Featured Editorial

1. Why The Biostatistician's Seat At The Table Keeps Vanishing 9/29/2026

   A Pfizer and Cytel veteran on why statisticians belong at trial design, and why fewer sponsors keep them in-house.

2. Is Moving From One-Off Solutions To A Technology Platform The Best Fit For Your R&D? 9/29/2026

   Integrated technology platforms can connect R&D data, accelerate trials, strengthen quality, and cut costs — but successful adoption requires more than AI.

3. From 73% Noncompliant To 2.4%: Building A Compliance Office 9/28/2026

   How one research administrator cut a university's clinical trial disclosure noncompliance from 73% to 2.4% in two years, then built a second office.

4. How AI Is Used To Predict Trial Performance Before Enrollment 9/24/2026

   AI and early digital twin models can help forecast trial performance, refine site feasibility, and anticipate operational needs before enrollment begins.

5. Two Planning Mistakes That Quietly Sink Clinical Programs 9/22/2026

   A veteran biostatistician on the planning document and the dose-selection shortcut that quietly decide whether trials succeed.

6. Token Costs Will Decide Clinical Supply AI 9/21/2026

   AI may make clinical supply forecasting faster, but cheaper tokens can drive higher costs. See how to measure AI at scale before a pilot becomes an expensive surprise.

7. A Framework For Diagnosing Clinical Research Technology Maturity 9/21/2026

   A 30-year clinical research veteran breaks down the four stages of technology maturity and why most organizations misjudge their own.

8. Clinical Trial Sites Don't Need More Tech, They Need Fewer Silos 9/17/2026

   Disconnected systems – not a lack of technology – are slowing clinical trial execution and forcing site staff to bridge costly workflow gaps.

9. A Biostatistician's Caution Around Digital Twins In Trials 9/15/2026

   A veteran statistician explains why she’s unconvinced digital twins can replace randomization in clinical trials, at least for now.

10. Who Owns Data Quality? The Authority Gap Slowing Trials 9/14/2026

    A former Bayer medical affairs lead explains why data-quality decisions land with whoever controls the budget, not whoever understands the data.